This monthly feature will help readers keep current on new drugs, new indications, dosage forms, and safety-related changes in labeling or use. Efforts have been made to ensure the accuracy of this information; however, if there are any questions, please let me know at bakerdan@wsu.edu. Product labeling: http://us.eisai.com/package_inserts/BelviqPI.pdf Mirabegron -Myrbetriq (Astellas) Comparative agents: Darifenacin, Fesoterodine, Oxybutynin, Solifenacin, Tolterodine, Trospium Indication: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency Mechanism of action: Beta-3 adrenergic agonist Common adverse effects: Hypertension, nasopharyngitis, urinary tract infection, and headache Dosage form & strength: Extended-release tablets: 25 mg and 50 mg Product labeling:
Comparative agents: Phentermine
Indication:
Adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:
• 30 kg/m 2 or greater (obese) or • 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, dyslipidemia, type 2 diabetes)
Mechanism of action:
Serotonin 2C receptor agonist New formulation is being referred to as a second-generation product that allows expanded stability profile and prolonged storage capacity. The original formulation is marketed under the trade name of Flolan.
New indications
Cetuximab Erbitux (Bristol-Myers Squibb)
Indication for colorectal cancer is expanded to include treatment in combination with FOLFIRI (FOL = leucovorin calcium [folinic acid]; F = fluorouracil; IRI = irinotecan hydrochloride) for first-line treatment of K-Ras mutation-negative (wild-type), epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal cancer.
Immune globulin infusion (human)
Gammagard liquid 10% (Baxter International)
Treatment of multifocal motor neuropathy No additional clinical trial data were required, but information may need to be supplied to the FDA regarding marketing exclusivity to pediatric patients.
Recommended for NONapproval by an FDA advisory panel
Tafamidis meglumine Vyndaqel
More clinical information has been requested on its effectiveness in the treatment of transthyretin familial amyloid polyneuropathy. 
